Author(s)

Huiya Wang^1,2,3,4, Yuzhou Li^1,2,3,4*, Jinlin Song^1,2,3,4*

¹College of Stomatology, Chongqing Medical University, Chongqing, China.
²Chongqing Key Laboratory of Oral Diseases, Chongqing, China.
³Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing, China.
⁴Chongqing Municipal Health Commission Key Laboratory of Oral Biomedical Engineering, Chongqing, China.

Diabetic periodontitis (DP) presents a complicated therapeutic challenge driven by microbial dysbiosis, immune dysregulation, and impaired tissue repair. Conventional treatments often fail to achieve predictable regeneration in this high-risk scenario due to the unique hyperglycemic and pro-inflammatory microenvironment. This review examines the paradigm shift in therapies offered by fast developing nanotechnology, moving beyond simple pathogen control toward integrated strategies. In this review, we identify different functional nanomaterial classes, including potent antibiofilm agents, immunomodulators designed to reprogram macrophage phenotypes and scavenge reactive oxygen species, and “smart” carriers enabling enzyme-responsive delivery. Furthermore, the role of nanocomposite scaffolds in facilitating alveolar bone regeneration is also highlighted. Beyond therapeutic mechanisms, we rigorously evaluate translational barriers, including biocompatibility, manufacturing consistency, and regulatory requirements. A critical emphasis is placed on the current scarcity of clinical data specifically derived from DP cohorts. The review concludes by forecasting the development of multifunctional, theranostic nanoplatforms that seamlessly integrate into clinical workflows, addressing the specific metabolic and inflammatory demands of DP to ensure safety and unlock their full therapeutic potential.

Diabetic Periodontitis, Nanotechnology, Immunomodulation, Tissue Regeneration

Wang, H.Y., Li, Y.Z. and Song, J.L. (2026) Current Progress in Nanomaterials for Diabetic Periodontitis Therapy. Journal of Biosciences and Medicines, 14, 239-257. doi: 10.4236/jbm.2026.144019.